Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
biote (BTMD)
NASDAQ:BTMD
Holding BTMD?
Track your performance easily
Earnings Data
Report Date
Apr 01, 2025TBA Not Confirmed
Period Ending
2024 (Q4)Consensus EPS Forecast
$0.12Last Year’s EPS
-$0.06Same Quarter Last Year
Strong Buy
Based on 4 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Nov 12, 2024
|% Change Since: 10.51%
|Next Earnings Date:Apr 01, 2025
Earnings Call Sentiment|Neutral
The earnings call reflected a mixed sentiment with strong financial performance and growth in key areas like dietary supplements, but faced challenges due to software disruptions and natural disasters affecting procedure volumes. The company is optimistic about overcoming these temporary setbacks and achieving growth in 2025.Company Guidance
During the Biote Third Quarter 2024 Earnings Conference Call, the company reported a 12.8% increase in total revenue, reaching $51.4 million, and a 7.1% growth in procedure revenue. Dietary supplement revenue saw a significant rise of 21.7% year-over-year, driven by improvements in their Amazon business. The gross profit margin improved by 160 basis points to 17.5%, while adjusted EBITDA grew to $16.2 million, with a margin of 31.5%. Despite temporary disruptions from software enhancements and hurricanes, Biote adjusted its 2024 financial guidance to a revenue range of $197 million to $201 million and adjusted EBITDA of $58 million to $61 million. The company expects procedure revenue growth to reaccelerate in 2025 as they continue to expand their network and enhance their product offerings.Strong Financial Performance
Biote delivered double-digit growth in both revenue and adjusted EBITDA for Q3 2024, with revenue reaching $51.4 million, up 12.8% from the prior quarter. Adjusted EBITDA improved approximately 15% compared to the same quarter last year and margins exceeded 30%.
Dietary Supplement Business Growth
Third quarter dietary supplement revenue increased 21.7% year-over-year, driven by improvements in the Amazon channel.
Vertical Integration and Cost Savings
Cost savings from the vertical integration of Asteria Health contributed to improved gross profit margin, which increased by 160 basis points from Q3 2023.
Cash Flow and Financial Position
Biote generated strong cash flow from operations, with a 9-month year-to-date total of $32.9 million compared to $19.9 million for the same period in 2023. Cash and cash equivalents at the end of Q3 2024 were $38.2 million, up from $26.4 million at the end of Q2 2024.
---
BTMD Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
BTMD Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Nov 12, 2024 | $5.52 | $6.72 | +21.74% |
| Aug 08, 2024 | $6.77 | $5.49 | -18.91% |
| May 07, 2024 | $5.77 | $6.07 | +5.20% |
| Mar 12, 2024 | $5.30 | $6.09 | +14.91% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does biote (BTMD) report earnings?
biote (BTMD) is schdueled to report earning on Apr 01, 2025, TBA Not Confirmed.
What is biote (BTMD) earnings time?
biote (BTMD) earnings time is at Apr 01, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is BTMD EPS forecast?
BTMD EPS forecast for the fiscal quarter 2024 (Q4) is $0.12.
---